Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.80 |
| ▸ | RAB9A | P51151 | 6/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.74 |
| ▸ | MEN1 | O00255 | 3/20 | 0.74 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | GFER | P55789 | 1/20 | 0.65 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.58 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.56 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.56 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.56 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.56 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.56 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7703395 | 0.89 | RAB9A (1.00) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL1331793 | 0.83 | NPC1 (0.79) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4041461 | 0.81 | KMT2A (0.63) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL20641182 | 0.79 | RAB9A (0.65) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL8288231 | 0.79 | RAB9A (0.65) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3407381 | 0.79 | RAB9A (0.65) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL1368482 | 0.79 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL8668493 | 0.79 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL12020749 | 0.78 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL1570073 | 0.78 | NPC1 (0.75) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281871-A1 | TAAR1 LIGANDS | GALLEY GUIDO (DE) | 2011-11-17 | — | — | US | disclosed |
| US-20110281871-A1 | TAAR1 LIGANDS | GALLEY GUIDO (DE) | 2011-11-17 | — | — | US | disclosed |
| US-20110281871-A1 | TAAR1 LIGANDS | GALLEY GUIDO (DE) | 2011-11-17 | — | — | US | disclosed |
| US-8008305-B2 | TAAR1 ligands | HOFFMANN-LA ROCHE INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008305-B2 | TAAR1 ligands | HOFFMANN-LA ROCHE INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008305-B2 | TAAR1 ligands | HOFFMANN-LA ROCHE INC. (US) | 2011-08-30 | — | — | US | disclosed |
| CN-101784515-A | Pyridinecarboxamide and benzamide derivatives as taar1 ligands | HOFFMANN LA ROCHE | 2010-07-21 | — | — | CN | disclosed |
| EP-2185502-A1 | PYRIDINECARBOXAMIDE AND BENZAMIDE DERIVATIVES AS TAAR1 LIGANDS | F. Hoffmann-Roche AG (CH) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009019149-A1 | PYRIDINECARBOXAMIDE AND BENZAMIDE DERIVATIVES AS TAAR1 LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | WO | disclosed |
| WO-2009019149-A1 | PYRIDINECARBOXAMIDE AND BENZAMIDE DERIVATIVES AS TAAR1 LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | WO | disclosed |
| US-20090036452-A1 | TAAR1 LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036452-A1 | TAAR1 LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036452-A1 | TAAR1 LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036452-A1 | TAAR1 LIGANDS | TAAR1, TAAR5, NPSR1 | NPC1 1378/4885RAB9A 2200/4885SMN1; SMN2 2022/4885 |
| US-20110281871-A1 | TAAR1 LIGANDS | TAAR1, TAAR5, NPSR1 | NPC1 1378/4885RAB9A 2200/4885SMN1; SMN2 2022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.